BioCentury | Feb 14, 2020
Product Development

AML’s growing options

For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come...
BC Extra | Dec 20, 2019
Financial News

Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

Forma’s $100 million in series D financing will fuel the company's push to join the wave of progress in sickle cell disease and complete its transformation from a chemistry research organization to a therapeutics company...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
BC Extra | May 15, 2019
Clinical News

May 15 Clinical Quick Takes: Principia, Agios, Y-mAbs, Pfizer

Principia gets $30M from Sanofi for Phase IIb MS trial start  Principia Biopharma Inc. (NASDAQ:PRNB) said partner Sanofi (Euronext:SAN; NASDAQ:SNY) began a Phase IIb trial of SAR442168 to treat relapsing multiple sclerosis, triggering a $30...
BioCentury | May 3, 2019
Product Development

Independents’ day: after their first solo launch, biotechs look to new partnering strategies

Having taken their first products to market alone, the new class of independent biotechs face decisions for what to keep and what to change as they seek to build sustainable value as end-to-end companies. One...
BC Extra | May 2, 2019
Company News

May 2 Company Quick Takes: Agios, Celgene/Presage, Purdue, Amgen/Syapse

Label expansion in AML for Agios’ Tibsovo  FDA approved an sNDA for Tibsovo ivosidenib from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) as monotherapy for adults with newly diagnosed acute myelogenous leukemia (AML) with a susceptible isocitrate dehydrogenase...
BioCentury | Apr 26, 2019
Product Development

Rise of the independents, biotechs go to market

While product launch and commercialization has largely been the province of big biotech and big pharma, with smaller companies partnering to get their products over the finish line, BioCentury’s analysis of recent FDA approvals finds...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Week In Review | Nov 30, 2018
Clinical News

FDA approves two drugs for first-line AML

FDA approved on Nov. 28 two drugs for first-line treatment of acute myelogenous leukemia, setting off a race in a setting that's been void of new approvals for patients who do not harbor an FMS-like...
Items per page:
1 - 10 of 127